Janone advances its potential peripheral artery disease and covid-19 vascular inflammation treatment towards trial readiness

Janone advances its potential peripheral artery disease and covid-19 vascular inflammation treatment towards trial readiness.janone inc - engineering batch for jan101 complete and expectations are for gmp batch production to begin within 30 days.janone - expects to deliver 250,000 doses within 30 days after start of manufacturing & have gmp batches of more than 20 million doses ready next year.janone inc - expects to submit investigational new drug for treatment of covid-19 vascular complications in coming weeks.
JAN Ratings Summary
JAN Quant Ranking